Effects of Mango on Insulin Sensitivity in Prediabetes

NCT07886372 | Not Yet Recruiting

• 1 other identifier: IRB-2026-47
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether daily mango consumption for 6 weeks can improve glucose utilization in individuals with prediabetes. The findings from this research may help explore the potential role of mangoes in a healthy diet for people at risk of developing type 2 diabetes

Conditions

Pre Diabetes

Outcome Measures

Primary Outcomes (3)

• Fasting Plasma Glucose Concentration

  Fasting plasma glucose concentration will be measured in plasma samples using a Randox automated clinical analyzer.

  Baseline and Week 6

• Fasting Plasma Insulin Concentration

  Fasting plasma insulin concentration will be measured in plasma samples using a Randox automated clinical analyzer.

  Baseline and Week 6

• Insulin Sensitivity

  The Matsuda index for insulin sensitivity will be calculated using validated equations based on paired glucose and insulin values obtained during the Liquid Meal Tolerance Test (LMTT).

  Baseline and Week 6

Secondary Outcomes (5)

• Plasma Glutathione Peroxidase Activity

  Baseline and Week 6

• Plasma Superoxide Dismutase Activity

  Baseline and Week 6

• Expression of Nrf-2 Pathway Genes

  Baseline and Week 6

• Continuous Glucose Monitoring (CGM)

  7-day monitoring periods at baseline and Week 6

• Fasting Plasma Triglyceride Concentration

  Baseline and Week 6

Study Arms (2)

Mango beverage

EXPERIMENTAL

1 cup (165 grams) of mango smoothie twice a day.

Other: Mango juice

Control (no mango)

PLACEBO COMPARATOR

calorie-matched control intervention

Other: Control Beverage

Interventions

Mango juice OTHER

Mango beverage

Mango beverage

Control Beverage OTHER

Italian Ice beverage

Control (no mango)

Eligibility Criteria

• Age: 25 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Be between 25-60 years old.
• Have a BMI of 25-35 kilograms per square meter.
• Have fasting blood glucose between 100-125 milligrams per deciliter or Glycated hemoglobin (HbA1c) between 5.7-6.4%.
• Be non-smokers for at least 12 months.
• Be generally healthy, with no major organ-related diseases.
• Not take medications or supplements that could interfere with the study.
• Be able to follow study procedures, including dietary restrictions and scheduled visits.

You may not qualify if:

• Smoke, vape, or use marijuana.
• Have allergies or intolerance to mangoes or study foods.
• Have blood pressure above 160/100 millimeters of Mercury.
• Have fasting blood glucose above 125 milligrams per deciliter.
• Have a history of major heart disease, stroke, or cancer in the past five years.
• Be pregnant, planning to become pregnant, or breastfeeding.
• Take anti-inflammatory drugs or certain dietary supplements.
• Have had major surgery or trauma in the past two months.
• Follow extreme diets (e.g., vegan, Atkins).
• Have used antibiotics in the last six weeks.
• Have a history of eating disorders or substance abuse in the past two years.
• Drink more than three cups of coffee or tea per day.
• Have donated blood in the last three months.
• Be professional athletes or do excessive exercise.
• Have had weight changes of more than 11 pounds in the past two months.

Sponsors & Collaborators

• Clinical Nutrition Research Center, Illinois Institute of Technology: lead
• National Mango Board: collaborator

Study Sites (1)

Clinical Nutrition Research Center

Chicago, Illinois, 60616, United States

Location

MeSH Terms

Conditions

Glucose Intolerance

Condition Hierarchy (Ancestors)

Hyperglycemia; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Britt Burton-Freeman, PhD

  Illinois Institute of Technology

  PRINCIPAL INVESTIGATOR

• Amandeep Sandhu, PhD

  Illinois Institute of Technology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Indika Edirisinghe, PhD

CONTACT

708-308-0178; iedirisi@illinoistech.edu

Chelsea Preiss, M.S.

CONTACT

312-567-5300; cpreiss@illinoistech.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: Single-blind
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The proposed study is a randomized, 2-arm, parallel design lasting approximately 6 weeks.

Study Record Dates

• First Submitted: October 7, 2026
• First Posted: October 21, 2026
• Study Start (Estimated): October 28, 2026
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): December 29, 2027
• Last Updated: October 21, 2026

Record last verified: 2026-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)